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Abstract
Background: Control and eradication of intestinal infections caused by protozoa are important
biomedical challenges worldwide. Prophylactic control of coccidiosis has been achieved with the
use of anticoccidial drugs; however, the increase in anticoccidial resistance has raised concerns
about the need for new alternatives for the control of coccidial infections. In fact, new strategies
are needed to induce potent protective immune responses in neonatal individuals.
Methods: The effects of a dietary supplementation of mannan-oligosaccharide (yeast cell wall;
YCW) on the local, humoral and cell-mediated immune responses, and intestinal replication of
coccidia were evaluated in a neonatal animal model during natural exposure to Eimeria spp. A total
of 840 one-day-old chicks were distributed among four dietary regimens: A) Control diet (no
YCW) plus anticoccidial vaccine); B) Control diet plus coccidiostat; C) YCW diet plus anticoccidial
vaccination; and D) YCW diet plus coccidiostat. Weight gain, feed consumption and immunological
parameters were examined within the first seven weeks of life.
Results: Dietary supplementation of 0.05% of YCW increased local mucosal IgA secretions,
humoral and cell-mediated immune responses, and reduced parasite excretion in feces.
Conclusion: Dietary supplementation of yeast cell wall in neonatal animals can enhance the
immune response against coccidial infections. The present study reveals the potential of YCW as
adjuvant for modulating mucosal immune responses.
Background
Control and eradication of intestinal infections caused by
protozoa are important biotechnological and medical
challenges worldwide. The coccidial parasites Eimeria,
Toxoplasma, Neospora and Cryptosporidium are the cause of
serious diseases in humans and animals. Many of these
intracellular protozoa affect the small intestine and pro-
duce devastating effects on immune compromised sub-
jects [1-3]. These parasitic infections can cause a wide
range of harm to the infected host; from diarrhea to abor-
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tion, death or chronic nutritional and cognitive sequels
[4,5]. Coccidial infections have been controlled, to a great
extent, with the use of anticoccidial drugs; however, the
increase in resistance to many of these products has raised
concerns about the need for new anticoccidial alternatives
[4]. A challenging factor is that protozoan parasites multi-
ply inside of host cells; thus, cell mediated immune
responses are required for protective immunity [4,5].
Therefore, development of effective anticoccidial strate-
gies requires substantial knowledge of the parasite biology
and host-parasite interactions [4].
Progress on new anticoccidial strategies has been accom-
plished in livestock and poultry. In these animal species,
protozoan intestinal infections are an important factor
associated with poor performance and production effi-
ciency [4,6,7]. Avian coccidiosis, caused by the apicompl-
exan protozoan Eimeria, is the major parasitic disease of
poultry. For the world poultry industry, the cost of coccid-
iosis excess USD 3 billion annually [6].
Currently, prophylactic protection against coccidiosis in
humans and animals can be accomplished with the use of
anticoccidial vaccines. However, the use of live vaccines
has been gradually adopted mainly due to economic rea-
sons such as elevated cost of vaccination and adverse
effects on early growth [4,8-10]. Even though research and
development of effective vaccine formulations are still in
progress [11,12], there is a need for new studies focused
on the design of novel strategies to induce potent protec-
tive immune responses without adverse effects in neonate
or immune-compromised individuals [4,13,14]. Here, a
neonatal animal model was used to examine the effect of
a dietary supplementation of mannan-oligosaccharide (in
the form of yeast cell wall (YCW) on the local and
humoral immune responses in neonatal chickens during
natural exposure to coccidia parasite. This study revealed
that dietary supplementation of 0.05% of YCW increases
local, cellular and humoral immune responses, and
reduces parasite excretion in feces.
Methods
Experimental design and animals
A total of 840 one-day-old Ross 308 chicks were distrib-
uted randomly in 28 pens bedded with fresh wood shav-
ings (30 chickens per pen; 1:1 female/male ratio) in an
experimental poultry house. The temperature was 32°C in
each room on day 1 and was decreased weekly until the
minimum temperature of 21°C was reached. Chickens
were fed conventional starter (1 to 21 days old) and fin-
isher (22 to 49 days) sorghum/soy based diets that met
National Research Council requirements (Nutrient
requirement of poultry, 1994). Fluorescent lighting was
provided under the following schedule: day 0–2: 23 h
light and 1 h dark, day 3–11: 18 h light and 6 h dark; day
12-end: 16 h light and 8 h dark. Chicks were allowed to
consume feed and water ad libitum during the entire time
of the experiment. The experiments were performed under
poultry farm conditions, where animals are naturally
exposed to different species of Eimeria (i.e. E. acervulina, E.
maxima  and  E. tenella; [13]). Experimental procedures
were approved by the Institutional Committee for Care
and Use of Experimental Animals at the Facultad de
Medicina Veterinaria y Zootecnia, Universidad Nacional
Autónoma de México.
Basal diets were formulated without antibiotics and were
identical across treatments with the following exceptions:
treatments B and D included coccidiostat [125 ppm of
nicarbazin (Helm, Naucalpan, Mexico) for starter diet and
65 ppm of salinomycin (Helm, Naucalpan, Mexico) for
finisher diet]. Treatments C and D included 0.05% (w/w)
of YCW (a concentrate of yeast hulls obtained via autoly-
sis of Saccharomyces cerevisiae (Safmex, Toluca, Mexico). At
arrival, chicks were randomly divided among treatments.
The experimental design was a factorial arrangement of
treatments, consisting of four dietary regimens: A) Con-
trol diet (no YCW) plus anticoccidial vaccine); B) Control
diet (no YCW) plus coccidiostat; C) YCW diet plus antic-
occidial vaccination; and D) YCW diet plus coccidiostat [7
replicates (pens) of each group, for a total of 210 animals
per treatment]. Animals from the vaccinated groups were
individually vaccinated at day 1 of age with a single oral
dose of a commercial vaccine against coccidia (Advent
cocci-vaccine; Viridus Animal Health LLC – Novus Inter-
national Inc., St. Louis, MO) following the manufacturer's
specifications. Animal weight gain and feed consumption
were recorded at 21 and 49 days of age. At the end of the
experimental period (49 days), 20 birds per treatment
were euthanized by cervical dislocation. Carcass yield and
breast skin pigmentation (yellow pigmentation after cold
processing analyzed by reflectance colorimetric, Minolta-
CR 400) were measured.
Assessment of the humoral immune response
The effect of different treatments on humoral immune
response was examined by means of antibody production
after a simultaneous vaccination against Newcastle dis-
ease virus (NDV). Ocular (eye drop 0.03 ml active virus,
Nobilis ND Lasota, Intervet/Schering-Plough Animal
Health; Mexico) and subcutaneous (0.25 ml inactivated
virus, Intervet/Schering-Plough Animal Health) vaccines
were administered at 10 days of age. Serum samples were
taken at 7 and 14 days post-vaccination (35 samples per
treatment), frozen at -20°C, and specific antibody titers
against NDV were determined by hemagglutination inhi-
bition assay [15].
Assessment of the mucosal immune response
The effect of different treatments on mucosal immune
response was examined by means of production of secre-
tory immunoglobulin A (IgA). Duodenum and trachealActa Veterinaria Scandinavica 2009, 51:11 http://www.actavetscand.com/content/51/1/11
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samples (10 chickens per treatment) were collected at 21
days of age to measure production of secretory IgA. Ten
centimeters of duodenum were taken and mucosal lav-
ages were performed with 10 ml of cold and sterile phos-
phate-buffered saline solution (PBS). Tracheal samples
were collected by tracheal swabs and placed (12 hrs) in
tubes containing 10 ml of sterile PBS. All mucosal samples
were clarified by centrifugation (1200 × g) and frozen at -
20°C. Secretory IgA concentrations were measured by
enzyme-linked immunosorbent assay (ELISA) test
(chicken IgA ELISA Quantitation Kit, Bethyl Laboratories
Inc. Montgomery, TX) following the manufacturer's pro-
tocol [16].
Assessment of the cell-mediated immune response
The effect of different treatments on cell-mediated
immune response was examined by cutaneous basophilic
hypersensitivity test [17,18]. Analysis of cell-mediated
immune response at 21 days was performed as descried
elsewhere [17]. Briefly, an intradermic inoculation of phy-
tohemagglutinin (PHA-A3; 0.1 mg/0.1 ml) was carried
out in the inter-digital membrane of 3rd and 4rd phalanges
of the right inferior extremity and sterile saline solution
(0.1 ml) of the left foot (35 chickens per treatment).
Twenty-four hours post-inoculation the thickness of the
inter-digital membrane was measured in millimeters
using a micrometer.
Assessment of the replication of coccidia in the intestinal 
tract
The effect of different treatments on the replication of coc-
cidia in the intestinal tract was estimated by quantifying
the number of oocysts excreted in feces. At 21 days of age,
ten birds per treatment were placed in separate cages with
clean sheets of paper on the bottom. Fecal samples were
collected from the paper lining after an 8-hour period.
Birds were returned to their respective pens at the end of
the fecal collection period. The total number of oocysts
was calculated following the method described previously
[19].
Statistical analysis
Results were statistically analyzed by ANOVA in a com-
plete randomized design with 2 × 2 factorial arrangement
and by the GLM procedure of the SAS software (SAS Insti-
tute, Cary, NC). Data of animal performance and immu-
nological parameters were grouped and presented as
mean ± SEM. P-values ≤ 0.05 were considered statistically
significant. Two factors were examined and compared
across the study, 1) diet: control sorghum/soy-based diet
(Control) vs. YCW diet (YCW); and 2) anticoccidial pro-
gram: anticoccidial vaccine (Vaccine) vs. coccidiostat drug
(Coccidiostat).
Results
Animal growth
The effects of diet and anticoccidial program on animal
performance at 21 and 49 days of age are described in
Table 1 and 2, respectively. At 21 days of age (Table 1),
YCW increased weight gain and feed consumption com-
pared to Control (P < 0.01). However, no significant dif-
ferences in feed conversion were observed between
Control and YCW (P > 0.05). Also, it was found that Coc-
cidiostat increased weight gain and feed consumption
compared to Vaccine (P  < 0.01), and that Vaccine
increased feed conversion (P < 0.05). These results reveal
the common adverse effects on growth of chicks caused by
anticoccidial vaccination [8]. In the analysis at 49 days of
age (Table 2), YCW increased weight gain and reduced
feed conversion compared to Control (P < 0.05). There
were no differences in percentage of carcass yield and skin
pigmentation between Control and YCW (P > 0.05; data
not shown). Also, there were no differences (P > 0.05) in
weight gain, feed consumption, feed conversion (Table
2), percentage of carcass yield and skin pigmentation
between Coccidiostat and Vaccine factors at day 49 of age
(data not shown).
Table 1: Effect of yeast-cell-wall (YCW) diet on growth in chickens during the first 3-weeks of age under coccidial infection
Weight gain (g) Feed consumption (g) Feed conversion
Diet
Control 750 ± 14b 1009 ± 10.27b 1.34 ± 0.03
YCW 779 ± 16a 1047 ± 16.91a 1.34 ± 0.02
Anticoccidial program
Coccidiostat 805 ± 14.0a 1051 ± 12.47a 1.30 ± 0.02b
Vaccine 725 ± 8.4b 1005 ± 20.13b 1.38 ± 0.03a
Variation source Probability
Diet 0.001 0.007 0.965
Anticoccidial program 0.037 0.019 0.005
Sample size per group 210 210 210
Two factors were examined and compared across the study, 1) diet: control diet (Control) vs. YCW diet (YCW); and 2) anticoccidial program: 
anticoccidial vaccine (Vaccine) vs. coccidiostat drug (Coccidiostat). Values in the same column with different superscripts (within factors) are 
statistically significant. Mean + SEM. P-values ≤ 0.05 were considered statistically significant.Acta Veterinaria Scandinavica 2009, 51:11 http://www.actavetscand.com/content/51/1/11
Page 4 of 7
(page number not for citation purposes)
Assessment of humoral immune response
The effect of different treatments on the humoral immune
response was examined by means of antibody production
after a simultaneous vaccination against NDV. Ocular and
subcutaneous vaccines were administered at 10 days of
age and antibody production was measured at 7 and 14
days post-vaccination (Table 3). At 14 days of age, YCW
induced higher NDV antibody titers compared to Control
(P < 0.01). There were no differences in antibody titers
between Vaccine and Coccidiostat (P  > 0.05). The
immune-regulatory effect was also observed at 21 days of
age. YCW induced the higher NDV antibody titers com-
pared to Control (P < 0.01). No significant effects were
observed between Vaccine and Coccidiostat factors (P >
0.05). These results reveal that YCW enhances the
humoral immune response against vaccine antigens in
young animals.
Assessment of mucosal immune response
The effect of different treatments on mucosal immune
response was examined by means of production of secre-
tory IgA. Results of the IgA concentrations are presented in
Table 3. In duodenal samples, YCW and Vaccine increased
mucosal concentrations of intestinal IgA compared to
Control and Coccidiostat, respectively (P < 0.01). In tra-
cheal samples, YCW increased concentrations of mucosal
IgA compared to Control (P < 0.05). No significant differ-
ences were observed between Vaccine and Coccidiostat.
Assessment of cell-mediated immune response
The effect of different treatments on cell-mediated
immune response was examined by the cutaneous
basophilic hypersensitivity test. This method reveals the
status of T-cell response. Results of the cell-mediated
immune response at 21 days are presented in Table 4.
YCW increased cell-mediated immune response com-
pared to Control (P < 0.05). No significant differences for
this parameter were observed between Vaccine and Coc-
cidiostat (P > 0.05). These results confirm the systemic
immune-regulatory effects of YCW and reveal that this
compound enhances cell-mediated immune responses in
young animals.
Table 2: Effect of yeast-cell-wall (YCW) diet on growth in chickens during the first 7-weeks of age under coccidial infection
Weight gain (g) Feed consumption (g) Feed conversion
Diet
Control 3060 ± 20.98b 5883 ± 58.67 1.92 ± 0.02a
YCW 3135 ± 38.21a 5854 ± 44.39 1.85 ± 0.04b
Anticoccidial program
Coccidiostat 3125 ± 39.42 5902 ± 51.41 1.87 ± 0.02
Vaccine 3069 ± 43.40 5835 ± 60.85 1.90 ± 0.03
Variation source Probability
Diet 0.045 0.227 0.021
Anticoccidial program 0.125 0.614 0.656
Sample size per group 210 210 210
For details see legend in Table 1. Values in the same column with different superscripts (within factors) are statistically significant. Mean + SEM. P-
values < 0.05 were considered statistically significant.
Table 3: Effect of yeast-cell-wall (YCW) diet on IgA production in mucosa and humoral immune responses to Newcastle disease virus 
(NDV) in neonatal chickens
Intestinal IgA (ng/ml) Tracheal IgA (ng/ml) Antibody titers* against 
NDV
17 days
Antibody titers against 
NDV
24 days
Diet
Control 622 ± 99.70b 83.61 ± 12.5b 3.11 ± 0.16b 5.55 ± 0.08b
YCW 1281 ± 152.1a 169.70 ± 13.2a 3.86 ± 0.05a 7.71 ± 0.09a
Anticoccidial program
Coccidiostat 450 ± 55.40b 145.55 ± 33.8 4.28 ± 0.58 6.57 ± 0.12
Vaccine 585 ± 143.2a 107.76 ± 20.2 4.07 ± 0.17 7.15 ± 0.09
Variation source Probability
Diet 0.009 0.011 0.015 0.005
Anticoccidial program 0.006 0.224 0.187 0.209
Sample size per group 10 10 35 35
For details see legend in Table 1. Values in the same column with different superscripts (within factors) are statistically significant. Mean + SEM. P-
values < 0.05 were considered statistically significant. *Log2.Acta Veterinaria Scandinavica 2009, 51:11 http://www.actavetscand.com/content/51/1/11
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Assessment of the replication of coccidia in the intestinal 
tract
The effect of the different treatments on the replication of
coccidia in the intestinal tract was verified by quantifying
the number of oocysts excreted in feces. Results of the
oocyst count at 21 days of age are presented in Table 4.
YCW reduced the number of oocysts excreted in feces
compared to Control (P < 0.01). Also, as expected, Coc-
cidiostat reduced oocyst excretion compared to Vaccine (P
< 0.05). These results reveal that the immune-regulatory
effects produced by YCW reduce the replication of coc-
cidia in the intestinal tract of young animals.
Discussion
The development of new strategies for control of coccidi-
osis is essential for the poultry industry. Chickens are
highly at risk for coccidial infections due to environmen-
tal conditions during production. High animal densities
(> 25,000 chickens per building) on floor pens and warm
surroundings are favorable for a high transmission, repli-
cation and accumulation of Eimeria spp. [13]. Moreover,
the current practices for animal production create a strong
selective pressure on coccidia parasites to develop anticoc-
cidial drug resistance [20]. Together, these factors make
neonatal chicken an excellent animal model for the study
and design of new and effective strategies for the control
of coccidiosis.
A current strategy for the control of avian coccidiosis is the
use of live anticoccidial vaccines; however, this approach
has been gradually accepted because of high cost of the
vaccine and some adverse effects on early animal growth
observed after vaccination [8]. In the present study, the
vaccinated group showed a negative effect on chicken
growth rates during the first 3-weeks of age; nonetheless,
by 7-weeks of age, this group had a compensatory growth
and the animal performance was similar among all groups
by the end of the experiment. In addition, the data of the
present study revealed that live-attenuated Eimeria spp.
strains contained in the anticoccidial vaccine were effec-
tive to replace intestinal replication and spreading of wild
Eimeria spp. strains. This notion is supported by the fact
that vaccinated birds excreted high numbers of oocysts in
feces with no effects on animal productivity. Although the
beneficial effects of anticoccidial vaccines in poultry are
well documented, the high costs associated with this pro-
phylactic approach limit its widespread use in animal pro-
duction [8]. To this end, the design of novel and not
expensive alternatives for the control of coccidiosis is an
important task to maintain the productivity of the poultry
industry.
The present study revealed that dietary supplementation
of 0.05% of YCW increases local mucosal IgA secretions,
cellular and humoral immune responses, and reduces par-
asite excretion in feces of neonatal animals infected with
coccidia. These results provide clear evidence of the poten-
tial of this dietary strategy as an anticoccidial alternative.
Specifically, this study reveals the potential of YCW die-
tary supplementation to enhance cell mediated immune
responses, an important factor for the protection against
coccidial infections [4,5,21].
In the present study, dietary supplementation of YCW
improved weight gain and feed conversion, and reduces
parasite excretion in feces of animals naturally infected
with coccidia. Only a few studies have examined the effect
of YCW on coccidial infections. Chickens supplemented
with yeast-culture residues in the diet and raised on coc-
cidia-infected litters [22]; and chickens fed with YCW and
experimentally infected with Eimeria  spp. [23] showed
improved growth performance compared to control treat-
ments. Results of all three reports consistently indicate
that dietary supplementation of YCW or derivates could
be an important alternative for reducing performance
losses provoked by coccidial infection.
Table 4: Effect of yeast-cell-wall (YCW) diet on cell-mediated immune responses and fecal excretion of coccidia oocysts in neonatal 
chickens
Basophilic hypersensitivity (mm2) Oocyst in feces (cells/g)
Diet
Control 0.56 ± 0.08a 32805 ± 572.80a
YCW 0.82 ± 0.09b 6505 ± 128.06b
Anticoccidial program
Coccidiostat 0.67 ± 0.12 2810 ± 2454.36b
Vaccine 0.71 ± 0.09 36500 ± 2308.66a
Variation source Probability
Diet 0.012 0.001
Anticoccidial program 0.682 0.001
Sample size per group 35 10
For details see legend in Table 1. Values in the same column with different superscripts (within factors) are statistically significant. Mean + SEM. P-
values < 0.05 were considered statistically significant.Acta Veterinaria Scandinavica 2009, 51:11 http://www.actavetscand.com/content/51/1/11
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The effects of diets supplemented with YCW on systemic
and local immune responses have been demonstrated in
many animal models including cows [24], pigs [25,26],
dogs [27,28], rats [29], chickens [30,31], rainbow trout
[32], etc. Likewise, it has been shown that YCW supple-
mented diets boost immune responses against vaccine
antigens; for example, in cows, YCW enhanced humoral
and cellular immune responses against rotavirus vaccine
[24]. In piglets, YCW improved humoral and cellular
immune responses against Aujeszky's disease vaccination
[25]. Interestingly, in humans, oral supplementation of a
yeast-based product significantly reduced the incidence
and duration of influenza outbreaks [33]. In the present
study, dietary supplementation of YCW increased the pro-
duction of antibodies against NDV and IgA concentra-
tions in the intestinal and tracheal mucosa. Moreover,
YCW supplementation reduced the number of Eimeria
spp. oocysts excreted in feces. A similar effect on parasite
oocysts excretion was reported elsewhere [34]. Although
the specific mechanisms of action by intestinal IgA on coc-
cidial infections are still unknown, it is thought that secre-
tory IgA attaches to the parasite surface and prevents its
binding to the intestinal epithelium. Also IgA reduces the
development of sporozoites or merozoites and prevents
invasion within host cells [35,36]. Interestingly, the
present study also revealed that the YCM treatment
increased IgA secretions in both the intestinal and tracheal
tissues while the vaccine treatment increased this anti-
body only in the intestinal samples. These observations
indicate that YCM treatment stimulate IgA secretions sys-
temically while the vaccine treatment stimulate secretions
only in tissues exposed to the parasite. These results, taken
together, provide new and clear evidence that YCW has an
immune-regulatory effect at the local and systemic level.
It can be hypothesized that the increase in humoral
responses induced by YCW supplementation are respon-
sible for the reduction in coccidia replication in the intes-
tinal mucosa [37]. However, recent evidence revealed that
humoral immunity plays only a minor role in protection
against this disease [4,35]. Cell-mediated immune
responses are thought to be the most important factor for
protection against coccidiosis. CD4+ and CD8+ T-cells
populations limit coccidia replication in the intestinal
tract [4,35,38]. The effects of T-cells on Eimeria spp. are
mediated by the cytokines that these cells release. Inter-
feron-gamma and tumor necrosis factor-alpha limit
oocyst production in either primary or secondary infec-
tions (for details see reviews [4,35,38]). The immune-reg-
ulatory effects of YCW on cell-mediated responses have
been confirmed in several human and animal studies [39-
42]. Therefore, it is possible to hypothesize that the reduc-
tion in Eimeria spp. replication in the intestine was caused
by the YCW-induction of T-cell responses. Even though T-
cells phenotypes were not directly examined in the
present study, cutaneous basophilic hypersensitivity test is
an excellent and well accepted method for the determina-
tion of T-cell response [17,18,43,44]. To our knowledge
this study provides the first evidence of the effect of YCW
on regulation of T-cell responsiveness, which could be
important for immunity against coccidial infections. Fur-
ther studies will elucidate T-cell repertoire and cytokines
responses stimulated by YCW dietary supplementation.
Conclusion
The present data show that dietary supplementation of
YCW in neonatal animals can enhance the immune
responses against coccidial infections. Moreover, the
present study provides a new dietary strategy for the alter-
native control of coccidiosis and more importantly, con-
firms the potential of YCW as adjuvant for modulating
mucosal immune responses [45]. Despite the difficulties
of designing effective approaches for the control of coccid-
iosis, this study provides a promising dietary strategy with
the potential to enhance the health of immune-compro-
mised subjects and children in developing countries.
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